EGFR and allergic disease: The enrollment criteria were: age 17–73 years old; KPS ≥ 70; adequate organ function; no known allergies; no history of mental illness; no drug abuse or other unhealthy habits; no metastasis or malignancy in other organ; no history of other malignancy, participation in other clinical trials, severe allergies, pregnancies, lactations, treatment of anti-EGFR; and tolerance to therapy.